hoodb.com

華上生醫(7427)公告上市藥品「剋必達錠(Tucidinostat/Kepida Tablets)」獲台灣衛福部受理新增適應症「用於治療復發或難治外周T細胞淋巴癌(R/R PTCL)」新藥查驗登記(NDA)之申請(12/11日股價36元)

|

You are leaving and open the following URL" of about "nda" news

news.google.com/rss/articles/CBMickFVX3lxTE5MY05FcF9zdURRaGxXeXB1dHhpTks4TTNzblE3OHl4Mnp5UHBhNlNLNXpmQjZ2b1N1TDJTUFZERnIxczVHM29xY1BPNG9iM3RreWpYVmxjdGtaRS1lczMzWUJicE1EUnhIV0RhM3dXajFvZw?oc=5


Continue Opne >

nda: 華上生醫(7427)公告上市藥品「剋必達錠(Tucidinostat/Kepida Tablets)」獲台灣衛福部受理新增適應症「用於治療復發或難治外周T細胞淋巴癌(R/R PTCL)」新藥查驗登記(NDA)之申請(12/11日股價36元)


More nda news:


1737071434-1737006394

About nda

from
1737071435-1736892698

Warning: filemtime(): stat failed for aCache/search/id/nda in /var/www/hoodb/function.php on line 339
1737071435-

nda, 華上生醫(7427)公告上市藥品「剋必達錠(Tucidinostat/Kepida Tablets)」獲台灣衛福部受理新增適應症「用於治療復發或難治外周T細胞淋巴癌(R/R PTCL)」新藥查驗登記(NDA)之申請(12/11日股價36元) 2022 nda

華上生醫(7427)公告上市藥品「剋必達錠(Tucidinostat/Kepida Tablets)」獲台灣衛福部受理新增適應症「用於治療復發或難治外周T細胞淋巴癌(R/R PTCL)」新藥查驗登記(NDA)之申請(12/11日股價36元)

Choose Your Country or Region


Back to Top



華上生醫(7427)公告上市藥品「剋必達錠(Tucidinostat/Kepida Tablets)」獲台灣衛福部受理新增適應症「用於治療復發或難治外周T細胞淋巴癌(R/R PTCL)」新藥查驗登記(NDA)之申請(12/11日股價36元)

Copyright © 2020-2021 hoodb.com. All Rights Reserved.